FindTrial
Sign In

A Comparison of the Safety and Comfort of AC-170

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01495338
Enrollment
60
Registered
2011-12-20
Start date
2011-12-31
Completion date
2011-12-31
Last updated
2017-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal Ocular Health

Brief summary

The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.

Interventions

DRUGAC-170 0.17%

1 drop in one eye at one timepoint

DRUGAC-170 0.24% (Formulation 1)

1 drop in one eye at one timepoint

DRUGAC-170 0.24% (Formulation 2)

1 drop in one eye at one timepoint

DRUGOlopatadine hydrochloride 0.2%/Tears Naturale II

1 drop in one eye at one timepoint

Sponsors

Aciex Therapeutics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able and willing to avoid the use of ocular medications or topical ocular preparations within protocol specific time period.

Exclusion criteria

* Known contraindications or sensitivities to the study medication or its components. * Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters. * Use of disallowed medications during the period indicated prior to the study enrollment or during the study.

Design outcomes

Primary

MeasureTime frameDescription
Drop Comfort Scoreduring 3 minute perioddrop comfort on 0-10 scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026